cash - 50,018
short term investments - 20,570
less liabilities - $58,104 stockholders equity
S8 filed 3-31 to sell shares and raise funds
$25 to $30 million expected for liquidation in quarter 3? Going to be an interesting quarterly filing to explain the math.
I'm thinking they will do all possible to wrap this up while Parsons is on board. Parsons background and the many hours put in the case are too valuable.
Of course Siga may not see it that way. Delay, delay, delay...while the contract money comes in and is cost expensed while salaries are paid expense accounts paid....Siga says eight years of delay has been very good for management pockets. More will be good.
% Held by Institutions1: 97.50%
These boys better have a 2 to 5 year outlook. If someone is forced to start selling a sizable position it could go down hard and fast.
Mooresboro is going to have to show full potential of 15M tons to keep the boys on board.
Maybe put the case on accelerated review. Parson's input is more valuable than most realize. You can google his background. Accelerated review does look prudent while they have Parsons on board.
I can still disagree on his damages awarded Pharmathene were far too low. Hope the DSC directs the settlement to a reasonable $240M plus interest.
Yes mymygbye this is the stock marktet where everything is based on best guess and speculation as to valuation, everything.
Royal Cluster at least through the fall. I think they said that last year at about this time. There excuses are all over the place for not having reached 15M/tons monthly a year ago. Hope to hear someone give a real target for what to expect as the achievable monthly output that can be expected from this new system they now have had a year of experimenting with. I for one will be shocked if 15M is still considered the practical target and someone is willing to put their name behind that target.
CBLI is a loser. That is why you research your investments and get the best informed and calculated speculation. As some of us did in Sept '06.
April 21, 2015
Filgrastim is the first radiation medical countermeasure to be approved under FDA’s Animal Rule, a regulation that permits approval of some products based on efficacy testing in animals and safety testing in humans. Filgrastim first received FDA approval in 1991 to ease treatment-related bone marrow damage in cancer patients and still is widely used for this purpose. Because testing of the drug’s ability to treat radiation-induced bone marrow injury could not be done ethically in humans, NIAID-funded researchers developed and characterized a macaque model of acute radiation injury. With filgrastim, 79 percent of animals survived 60 days after radiation exposure, compared to 41 percent without the drug. The filgrastim group also experienced fewer infections. All animals were given standard supportive care, including fluids, antibiotics, fever-reducers and pain medication.
Based on these NIAID-supplied data, an FDA advisory committee concluded in May 2013 that filgrastim is reasonably likely to benefit humans exposed to high radiation levels. The March 2015 approval of the drug for this indication will improve access to filgrastim in the event of a public health emergency related to radiation exposure.
An example of a very, very speculative "investment" as CBLI desperately needs NIH funding to continue their hopes of one day getting a BARDA order. There are other radiation plays progressing nicely if you google a little.
Siga lawyer up and hung on to it like a bulldog and did very well in Delaware Courts. Hundreds of millions of development money handled by the ill will crew. Now you have cost of goods associated expense accounts to add to generous salaries and stock awards. Siga could probably hand it over to PIP and be very happy with how much they already pocketed while the legal battle carried on.
The 0.1% knows how to get a ROI. I would imagine their has been a fortune made off of day traders as friends and associates traded from the inside leaks.
Anyone looking at some interesting investments that are profitable and underpriced right now?
Results announced that primates injected with lethal dose of smallpox treated with -246 all lived and had no or lower lesion burden. Primates not given 246 died.
Study impressed NIH and awarded tens of millions to complete study to gain approval to stockpile -246
Congress had special funding approved and set aside $5B to acquire bioterror solutions from biotech. Smallpox & Anthrax were considered the top two concerns to focus on when using the $5 billion.
CBLI - if they had a drug 100% effective in primate trials and showed no serious side effects in radiation exposure levels proven 100% fatal. With NIH funding in tens of millions granted to get their product to the finish line. Also, have billions approved by Congress set aside for stocking of the medication. With all those factors your speculation of value for CBLI would be interesting. Have you done any calculations and do you have the degree of certainty on a coming BARDA purchase?
Siga & Barda were talking in excess of $2 billion contract within a couple of years from Sept '06.
What are you speculating on with CBLI. And the only thing not speculative is death, so everything listed in DOW or NASDAQ is based on speculation.
Please update us on you CBLI speculation and any data you have. I may join you in the investment.
0.35% is very small and just posting the info for anyone wondering, PIP is not likely to get swept down by a biotech correction. Agree, anyone investing here should only pay attention to the Delaware Chancery.
First Quarter Financial Results
Revenues for the first quarter of 2015 totaled $67,000 compared with $50,000 for the same quarter last year.
A very slow start. How long before the company reaches $1M in sales? Even reaching $1 in (sales) it would be hard to justify the market cap.
Looks like a good buyout for a small or medium size company that has an effective sales staff in place.
Plenty of interest in the cash position when it comes to a buyout.
Building cash reserves in about the most favorable way possible, Oculus Innovative Sciences (NASDAQ: OCLS) announced on March 16 that it is padding its bank account without any dilution by selling part, and eventually all, of its stake in Ruthigen (NASDAQ: RTGN), a company it spun out into a separate public entity last year. Some may have seen this coming as Oculus said in January that it penned an agreement to sell two million shares of RTGN for $5.5 million to existing Ruthigen shareholders “if” a merger happens for Ruthigen.
RTGN divesture added to the $5.3 million raised in January plus the $2.2 million on hand at the end of 2014 (plus revenue in 2015, less expenses) has Oculus’ cash on hand nearing its $11.8 million market capitalization. O
Guess they are trying to tie up contracts before Iran is allowed to export another 1 million barrels daily. Iraq, (the hell hole) is actually increasing output. The ISIS thing is likely coming to a boil and the big boys need to show ISIS everyone in the area is very unhappy with their beheadings and stealing from surrounding areas to make things operate inside their territory.
BIS walked down? Wall Street operates in mysterious ways.
Approved for veterinarian use also. Looks like product to be bought out by a larger company?
Patience usually pay off.
I'm looking at it as an investment and the one year chart seems to reflect the huge miss in the production seen from Mooresboro. Latest promise:
We remain focused on ramping up to our interim goal of 75% of nameplate capacity, which we hope to achieve during the third quarter.”
(75%) goal after waiting this long is now the goal? ZINC is a show me stock. I'm really afraid their original calculations for Mooresboro may be unattainable. I do like the zinc sector and have it on my watch list. Hoping for the best but not ready to put money in at this price, yet.
Go bad faith and speculate on ill will penalty paid off. Siga management has done very well financially. The events announced in Sept '06 took out most of the speculation out of -246 being a very profitable future. Siga had a $2.6 B understanding with BARDA soon after.
Not to scare you mymy but everything in the market has speculative risk built into the price, if you're investing.